BIOTECH FINANCING SUMMARY October 201 4 · Argos Therapeutics, Inc. Therapeutics / Diagnostics...
13
Biotech Financin All data supplied a BIOTECH F INANCING September saw financing activit picking up the pace after the ind raised was USD 583m - the third the financing value raised by Eu 242m was the largest over the 1 high average deal value of USD 2 bigger than the second, achieve performance came right after a venture rounds were recorded i companies. On the other side of the Atlantic 341m. This figure was by 22% r smaller than the U.S. average o would suspect, September’s num compared to 19). Indeed, the av different path than that of their previous month and was by 34% In September, two European com Adaptimmune completed a USD financing. In what follows, we al Pharma and summarize the fina The graph contains only financing rounds of private rounds from previous months may alter as new info added. ng Summary and available from Biotechgate – www.biotec G SUMMARY ty for Biotech companies (Therapeutics a dustry’s summer slothfulness. The total fi d largest within the last 12 months, and w uropean companies. Specifically, Europe’s 12 months trailing and was achieved with 26.9m; the highest within the sample peri ed in October 2013 (USD17.9m). It is wort a diametrically opposite one seen in Augus in the region for Biotech (Therapeutics an c, the total financing value in September a reduced compared to that of August (USD over the period studied (USD 389m). Contr mber of U.S. rounds was well above the p verage financing value raised by U.S. com r European counterparts. It shrank by 46% % smaller than the period’s average for th mpanies raised the largest financing roun 104m Series A and Swiss Cardiorentis re lso highlight the raising of USD 40m by Bo ancing events within the industry for Septe e & independent biotech therapeutic and diagnostic companies. Fina ormation on financing rounds is received and/or new tranches to ex chgate.com 1 October 2014 and Diagnostics) inancing value was mainly driven by s total value of USD h an exceptionally iod and by 50% th noting that this st, in which no nd Diagnostics) amounted to USD D 438m) and 12% rary to what one period’s average (26 mpanies followed a % compared to the he region. nds. U.K. - based eceived a EUR 45m oston-based Flex ember 2014. ancing amounts and number of xisting financing rounds are Source: Biotechgate.com
Transcript of BIOTECH FINANCING SUMMARY October 201 4 · Argos Therapeutics, Inc. Therapeutics / Diagnostics...
Biotech Financing Summary
All data supplied and available from Biotechgate
BIOTECH FINANCING
September saw financing activity for Biotech companies (Therapeutics and Diagnostics)
picking up the pace after the industry’s summer slothfulness.
raised was USD 583m - the third largest within the
the financing value raised by European companies. Specifically, Europe’s total value of USD
242m was the largest over the 12 months
high average deal value of USD 26.9m; the highest with
bigger than the second, achieved in October 2013
performance came right after a diametrically
venture rounds were recorded in the region for Biotech (Therapeutics
companies.
On the other side of the Atlantic, the total financing value in September
341m. This figure was by 22% reduced compared to that of August (USD 438m) and 12%
smaller than the U.S. average over the period studied
would suspect, September’s number of U
compared to 19). Indeed, the average
different path than that of their European co
previous month and was by 34% smaller than the period’s average for the region.
In September, two European companies
Adaptimmune completed a USD 104m Series A and Swiss Cardiorentis received a EUR 45m
financing. In what follows, we also highlight the raising of USD 40m by
Pharma and summarize the financing events within
The graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amou
rounds from previous months may alter as new information
added.
Biotech Financing Summary
All data supplied and available from Biotechgate – www.biotechgate.com
INANCING SUMMARY
saw financing activity for Biotech companies (Therapeutics and Diagnostics)
picking up the pace after the industry’s summer slothfulness. The total financing value
the third largest within the last 12 months, and was mainly driven
raised by European companies. Specifically, Europe’s total value of USD
242m was the largest over the 12 months trailing and was achieved with an exceptionally
high average deal value of USD 26.9m; the highest within the sample period
bigger than the second, achieved in October 2013 (USD17.9m). It is worth noting that this
performance came right after a diametrically opposite one seen in August
venture rounds were recorded in the region for Biotech (Therapeutics and Diagnostics)
the other side of the Atlantic, the total financing value in September amounted to USD
341m. This figure was by 22% reduced compared to that of August (USD 438m) and 12%
smaller than the U.S. average over the period studied (USD 389m). Contrary to what one
, September’s number of U.S. rounds was well above the period’s average (26
compared to 19). Indeed, the average financing value raised by U.S. companies
than that of their European counterparts. It shrank by 46% compared to the
34% smaller than the period’s average for the region.
, two European companies raised the largest financing rounds. U.K.
Adaptimmune completed a USD 104m Series A and Swiss Cardiorentis received a EUR 45m
also highlight the raising of USD 40m by Boston
Pharma and summarize the financing events within the industry for September
he graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amou
hs may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are
www.biotechgate.com
1
October 2014
saw financing activity for Biotech companies (Therapeutics and Diagnostics)
The total financing value
was mainly driven by
raised by European companies. Specifically, Europe’s total value of USD
and was achieved with an exceptionally
period and by 50%
. It is worth noting that this
opposite one seen in August, in which no
and Diagnostics)
amounted to USD
341m. This figure was by 22% reduced compared to that of August (USD 438m) and 12%
Contrary to what one
rounds was well above the period’s average (26
raised by U.S. companies followed a
unterparts. It shrank by 46% compared to the
34% smaller than the period’s average for the region.
est financing rounds. U.K. - based
Adaptimmune completed a USD 104m Series A and Swiss Cardiorentis received a EUR 45m
Boston-based Flex
the industry for September 2014.
he graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amounts and number of
existing financing rounds are
Source: Biotechgate.com
Biotech Financing Summary
All data supplied and available from Biotechgate
Selected Financing Highlights
Adaptimmune secures USD 104
Oxford, U.K.-based Adaptimmune Limited, a biotechnology company focused on the use of T
cell therapy to treat cancer and infectious disease
completion of a USD 104m Series A financing round.
The oversubscribed round was led by New Enterprise Associates (NEA), and additional new
investors participating included OrbiMed Advisors LLC, Wellington Management Company,
LLP, Fidelity Biosciences, Foresite Capital Management,
Novo A/S, QVT, Rock Springs Capital, venBio Select and Merlin Nexus. Existing investors
participating included the University of Oxford and others.
Adaptimmune plans to use the proceeds from the Series A financing to advance
company’s internal programmes into the clinic in multiple cancer indications.
(Source: press release)
Cardiorentis Announces EUR 45m
Partners to Fund Ularitide Registration Program in Acute Heart Failure
Zug, Switzerland-based Cardiorentis AG, a privately
announced on the 17th of September 2014
agreement with HealthCare Royalty Partners (“HC Royalty”), a U.S. based healthcare
investment firm. The proceeds will be used to finance the Company’s registration program
for the natriuretic peptide Ularitide in acute heart failure.
The TRUE-AHF Phase III trial was initiated in August 2012. It is led by the international
principal investigator Milton Packer, M.D., University Texas, Southwestern Medical Center in
Dallas, Texas and includes over 200 centers across the U.S., Europe, Canada and Latin
America. TRUE-AHF is an event driven trial, which may enroll up to 4,000 patients with acute
heart failure. There are two co-
acute heart failure which assesses a patient’s symptoms and persistent or worsening heart
failure within the first 48 hours after treatment initiation. The second co
is cardiovascular mortality. (Source: press release
Biotech Financing Summary
All data supplied and available from Biotechgate – www.biotechgate.com
ighlights
104m in Series A Financing
Adaptimmune Limited, a biotechnology company focused on the use of T
cell therapy to treat cancer and infectious disease, announced on the 5th
Series A financing round.
The oversubscribed round was led by New Enterprise Associates (NEA), and additional new
participating included OrbiMed Advisors LLC, Wellington Management Company,
Biosciences, Foresite Capital Management, Ridgeback Capital Management,
Novo A/S, QVT, Rock Springs Capital, venBio Select and Merlin Nexus. Existing investors
participating included the University of Oxford and others.
Adaptimmune plans to use the proceeds from the Series A financing to advance
company’s internal programmes into the clinic in multiple cancer indications.
Cardiorentis Announces EUR 45m (USD 58.1m) Financing with HealthCare Royalty
Partners to Fund Ularitide Registration Program in Acute Heart Failure
Cardiorentis AG, a privately held biopharmaceutical company,
on the 17th of September 2014 that it has entered into a EUR 45m
agreement with HealthCare Royalty Partners (“HC Royalty”), a U.S. based healthcare
stment firm. The proceeds will be used to finance the Company’s registration program
for the natriuretic peptide Ularitide in acute heart failure.
AHF Phase III trial was initiated in August 2012. It is led by the international
tor Milton Packer, M.D., University Texas, Southwestern Medical Center in
Dallas, Texas and includes over 200 centers across the U.S., Europe, Canada and Latin
AHF is an event driven trial, which may enroll up to 4,000 patients with acute
-primary endpoints. The first is a composite endpoint for
acute heart failure which assesses a patient’s symptoms and persistent or worsening heart
failure within the first 48 hours after treatment initiation. The second co
Source: press release)
www.biotechgate.com
2
Adaptimmune Limited, a biotechnology company focused on the use of T-th of September the
The oversubscribed round was led by New Enterprise Associates (NEA), and additional new
participating included OrbiMed Advisors LLC, Wellington Management Company,
Ridgeback Capital Management,
Novo A/S, QVT, Rock Springs Capital, venBio Select and Merlin Nexus. Existing investors
Adaptimmune plans to use the proceeds from the Series A financing to advance the
company’s internal programmes into the clinic in multiple cancer indications.
Financing with HealthCare Royalty
Partners to Fund Ularitide Registration Program in Acute Heart Failure
held biopharmaceutical company,
that it has entered into a EUR 45m financing
agreement with HealthCare Royalty Partners (“HC Royalty”), a U.S. based healthcare
stment firm. The proceeds will be used to finance the Company’s registration program
AHF Phase III trial was initiated in August 2012. It is led by the international
tor Milton Packer, M.D., University Texas, Southwestern Medical Center in
Dallas, Texas and includes over 200 centers across the U.S., Europe, Canada and Latin
AHF is an event driven trial, which may enroll up to 4,000 patients with acute
primary endpoints. The first is a composite endpoint for
acute heart failure which assesses a patient’s symptoms and persistent or worsening heart
failure within the first 48 hours after treatment initiation. The second co-primary endpoint
Biotech Financing Summary
All data supplied and available from Biotechgate
Flex Pharma Raises USD 40m
Boston-based Flex Pharma, Inc., a biopharmaceutical company dedicated to creating
innovative, novel treatments for neuromuscular disorders, announced on the 8
September 2014 that it has raised USD 40m in private funding from a number of blue chip
public and private investors.
With this financing, Flex Pharma plans to further advance the science and its clinical
candidates addressing neuromuscular disorders
Flex Pharma Co-Founder and Co
MacKinnon M.D., who won the 2003 Nobel Prize in Chemistry commented: “Our early stage
clinical studies have shown initial human efficacy. We are hopeful that we may be able
help individuals suffering from muscle cramps and other neuromuscular disorders related
to muscle cramping in healthy volunteers
Biotech Financing Summary
All data supplied and available from Biotechgate – www.biotechgate.com
Flex Pharma, Inc., a biopharmaceutical company dedicated to creating
innovative, novel treatments for neuromuscular disorders, announced on the 8
September 2014 that it has raised USD 40m in private funding from a number of blue chip
With this financing, Flex Pharma plans to further advance the science and its clinical
candidates addressing neuromuscular disorders
Founder and Co-Chair of the Company’s Scientific Advisory Board, Rod
MacKinnon M.D., who won the 2003 Nobel Prize in Chemistry commented: “Our early stage
clinical studies have shown initial human efficacy. We are hopeful that we may be able
help individuals suffering from muscle cramps and other neuromuscular disorders related
to muscle cramping in healthy volunteers.” (Source: press release)
www.biotechgate.com
3
Flex Pharma, Inc., a biopharmaceutical company dedicated to creating
innovative, novel treatments for neuromuscular disorders, announced on the 8th of
September 2014 that it has raised USD 40m in private funding from a number of blue chip
With this financing, Flex Pharma plans to further advance the science and its clinical
Chair of the Company’s Scientific Advisory Board, Rod
MacKinnon M.D., who won the 2003 Nobel Prize in Chemistry commented: “Our early stage
clinical studies have shown initial human efficacy. We are hopeful that we may be able to
help individuals suffering from muscle cramps and other neuromuscular disorders related
Biotech Financing Summary
All data supplied and available from Biotechgate
Equity Financing Breakdown by
Diagnostics) – End of Most
In Q3 2014 the overall percentage of private biotech companies (Therapeutics and
Diagnostics) receiving mid-sized
highest of the last 5 quarters (55%).
15m represented 32% of the whole
while investments between USD 1
in size only when compared to their corresponding Q2 2014 figure (24%).
On the other hand, investments
system represented only 46% of all and were thus significantly shrunk compared with the
corresponding numbers seen within the last
however, the values of 32% and 14% for investments smaller than USD 5m and larger than
USD 30m respectively, are the second lowest ones
represented a smaller amount of investments in Q2 2014, while the second saw its
percentage in Q3 2013.
The graph above shows the proportion of financing for private biotech companies (therapeutics and diagnostics) by investment
The data-set includes only private Biotech (Therapeutics and Diagnostics)
Biotech Financing Summary
All data supplied and available from Biotechgate – www.biotechgate.com
reakdown by Investment size (Therapeutics &
ost Recent Quarter
2014 the overall percentage of private biotech companies (Therapeutics and
sized financings (between USD 5m and USD 30
(55%). Specifically, investments between USD
represented 32% of the whole - a higher percentage than in all 5 preceding quarters,
investments between USD 15m and USD 30m represented 23% of all and
in size only when compared to their corresponding Q2 2014 figure (24%).
n the other hand, investments occupying the extreme ranks within our classification
system represented only 46% of all and were thus significantly shrunk compared with the
corresponding numbers seen within the last 5 quarters. When looked at individually
, the values of 32% and 14% for investments smaller than USD 5m and larger than
are the second lowest ones within the sample. The first category
represented a smaller amount of investments in Q2 2014, while the second saw its
The graph above shows the proportion of financing for private biotech companies (therapeutics and diagnostics) by investment
Biotech (Therapeutics and Diagnostics) companies from the U.S. and Europe.
Source: Biotechgate.com
www.biotechgate.com
4
herapeutics &
2014 the overall percentage of private biotech companies (Therapeutics and
and USD 30m) was the
USD 5m and USD
a higher percentage than in all 5 preceding quarters,
represented 23% of all and were second
in size only when compared to their corresponding Q2 2014 figure (24%).
occupying the extreme ranks within our classification
system represented only 46% of all and were thus significantly shrunk compared with the
. When looked at individually
, the values of 32% and 14% for investments smaller than USD 5m and larger than
within the sample. The first category
represented a smaller amount of investments in Q2 2014, while the second saw its smallest
The graph above shows the proportion of financing for private biotech companies (therapeutics and diagnostics) by investment size
companies from the U.S. and Europe.
Source: Biotechgate.com
Biotech Financing Summary
All data supplied and available from Biotechgate
Total Value of Quarterly
Diagnostics) – 3-Year Historical
In Q3 2014 the total value of financing deals by private Biotech companies (Ther
Diagnostics) was USD 1,116m, the
2011 after those of Q2 2014 and Q3 2012. Compared to the previous quarter, the total
financing value was reduced by 45%, while the average deal size
European financing in Q3 2014 totaled USD 2
three years and by 15% larger than
financing value of the most recent
rounds. Indeed, the average deal size in Europe for
region over the past 12 quarters (USD 23.5m) and by 45% larger than the second biggest,
seen in Q4 2013 (USD 16.2m)
Being the main driver behind total financing values, the U.S. total financing value compares
with past quarters just as the value across both geographies.
U.S. in Q3 2014 was the third highest within our sample and
quarterly average (USD 712m).
The graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amo
and number of rounds from previous quarters may
existing financing rounds are added.
Biotech Financing Summary
All data supplied and available from Biotechgate – www.biotechgate.com
uarterly Financings Biotech (Therapeutics &
istorical Data
2014 the total value of financing deals by private Biotech companies (Ther
the third highest within the three-year period starting in Q
2011 after those of Q2 2014 and Q3 2012. Compared to the previous quarter, the total
financing value was reduced by 45%, while the average deal size was reduced
2014 totaled USD 258m, and was thus the third biggest of the past
than the corresponding Q2 2014 figure (USD 2
the most recent quarter was amassed in only 11 European venture
rounds. Indeed, the average deal size in Europe for Q3 2014 was the highest seen in the
region over the past 12 quarters (USD 23.5m) and by 45% larger than the second biggest,
ing the main driver behind total financing values, the U.S. total financing value compares
with past quarters just as the value across both geographies. The USD 858m raised in the
U.S. in Q3 2014 was the third highest within our sample and by 20% larger th
The graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amo
and number of rounds from previous quarters may alter as new information on financing rounds is received and/or new tranches to
www.biotechgate.com
5
herapeutics &
2014 the total value of financing deals by private Biotech companies (Therapeutics and
year period starting in Q3
2011 after those of Q2 2014 and Q3 2012. Compared to the previous quarter, the total
reduced by 28%.
the third biggest of the past
(USD 224m). The
quarter was amassed in only 11 European venture
was the highest seen in the
region over the past 12 quarters (USD 23.5m) and by 45% larger than the second biggest,
ing the main driver behind total financing values, the U.S. total financing value compares
The USD 858m raised in the
20% larger than the period’s
The graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amounts
alter as new information on financing rounds is received and/or new tranches to
Source: Biotechgate.com
Biotech Financing Summary
All data supplied and available from Biotechgate
Worldwide financing
Biotechnology - Therapeutics/Diagnostics
Private/independent Companies
Year 2013 2013 2013 2013
Month Sep Oct Nov Dec
Total 347 613 583 227
US 274 366 418 133
Europe 72 224 161 86
RoW1 1 22 4 8
1 Rest of the world.
The table above shows the total global financing in biotechnology in the therapeutics and diagnostics
Biotech Financing Summary
All data supplied and available from Biotechgate – www.biotechgate.com
Therapeutics/Diagnostics
2014 2014 2014 2014 2014 2014 2014
Jan Feb Mar Apr May Jun Jul
313 428 500 1192 518 543 355
211 304 401 989 437 480 259
89 113 86 159 81 63 67
14 11 13 45 0 0 29
the total global financing in biotechnology in the therapeutics and diagnostics subclass.
www.biotechgate.com
6
All units in USD M
2014 2014 2014 Grand
l Aug Sep Total
355 486 612 6717
259 438 341 5051
67 0 242 1443
29 48 29 223
subclass.
Biotech Financing Summary
All data supplied and available from Biotechgate
September 2014 financing rSource: Biotechgate – www.biotechgate.com
Company Name Sector
TransEnterix, Inc. Medical Technology
ChromaDex Inc. Biotechnology - other
Twist Bioscience Corp. R&D Services
Argos Therapeutics, Inc. Therapeutics / Diagnostics
Tetra Discovery
Partners
Therapeutics / Diagnostics
Allakos Inc. Therapeutics / Diagnostics
Cerebral Diagnostics
Canada Inc.
Medical Technology
Acutus Medical, Inc. Medical Technology
Lpath Incorporated Therapeutics / Diagnostics
Vitae Pharmaceuticals Therapeutics / Diagnostics
Suzou Xinrong Best
Medical Instrument Co.,
Ltd.
Medical Technology
BioMotiv, LLC Therapeutics / Diagnostics
Eutropics
Pharmaceuticals
Therapeutics / Diagnostics
Adaptimmune Limited Therapeutics / Diagnostics
Zyga Technology, Inc. Medical Technology
Biotech Financing Summary
All data supplied and available from Biotechgate – www.biotechgate.com
financing rounds summary www.biotechgate.com
Amount
m USD
Type of
Round
Financing
Stage
Medical Technology 25.0 Other Debt
financing
other 5.0 Other Post-IPO
10.0 Other Debt
financing
Therapeutics / Diagnostics 25.0 Other Debt
financing
Therapeutics / Diagnostics 1.0 UD Equity -
Seed
Diagnostics 10.0 Series A / 1.
Round
Equity -
Start-up
Medical Technology 0.9 Series A / 1.
Round
Equity -
First stage
Medical Technology 26.2 Series B / 2.
Round
Equity -
Start-up
Therapeutics / Diagnostics 12.5 Other Post-IPO
Therapeutics / Diagnostics 48.4 Other IPO
Medical Technology 100.0 UD Equity -
Later stage
Therapeutics / Diagnostics 25.0 UD Other
Therapeutics / Diagnostics 1.5 Other Research
grants
Therapeutics / Diagnostics 104.0 Series A / 1.
Round
Equity -
First stage
Medical Technology 10.0 Other Other
www.biotechgate.com
7
Ownership Country
Public USA
Public USA
Private /
independent
USA
Public USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
Canada
Private /
independent
USA
Public USA
Public USA
Private /
independent
China
Private /
independent
USA
Private /
independent
USA
Private /
independent
United
Kingdom
Private /
independent
USA
Biotech Financing Summary
All data supplied and available from Biotechgate
Agrisoma Biosciences
Inc.
Biotechnology - other
Avanir Pharmaceuticals,
Inc.
Therapeutics / Diagnostics
Allele Biotechnology and
Pharmaceuticals, Inc.
R&D Services
VentiRx
Pharmaceuticals, Inc.
Therapeutics / Diagnostics
Inivata R&D Services
Ivantis, Inc. Medical Technology
Navidea
Biopharmaceuticals, Inc.
Therapeutics / Diagnostics
Oncoceutics, Inc. Therapeutics / Diagnostics
Minerva Surgical Inc. Medical Technology
Eureka Therapeutics,
Inc.
Therapeutics / Diagnostics
PlantForm Corporation Therapeutics / Diagnostics
Syndax
Pharmaceuticals, Inc.
Therapeutics / Diagnostics
CVRx, Inc. Medical Technology
TRACON
Pharmaceuticals, Inc.
Therapeutics / Diagnostics
Aeras Therapeutics / Diagnostics
iHealth Lab, Inc. Medical Technology
Soligenix, Inc. Therapeutics / Diagnostics
Biotech Financing Summary
All data supplied and available from Biotechgate – www.biotechgate.com
other 7.3 Series A / 1.
Round
Equity -
First stage
Therapeutics / Diagnostics 200.2 Other Post-IPO
7.0 Series A / 1.
Round
Equity -
First stage
Therapeutics / Diagnostics 19.3 UD Equity -
Second
stage
6.5 UD Other
Medical Technology 25.0 Series B / 2.
Round
Equity -
Start-up
Therapeutics / Diagnostics 1.7 Other Research
grants
Diagnostics UD UD Equity -
Start-up
Medical Technology 25.0 Other Equity -
Seed
Therapeutics / Diagnostics 21.0 Series C / 3.
Round
Equity -
Second
stage
Therapeutics / Diagnostics 20.0 Other Private
placement
Therapeutics / Diagnostics 5.0 Other Debt
financing
Medical Technology 15.0 Other Debt
financing
Therapeutics / Diagnostics 27.0 Series B / 2.
Round
Equity -
Second
stage
Therapeutics / Diagnostics 2.0 Other Research
grants
Medical Technology 25.0 Series A / 1.
Round
Equity -
Start-up
Therapeutics / Diagnostics 24.7 Other Research
grants
www.biotechgate.com
8
Private /
independent
Canada
Public USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
United
Kingdom
Private /
independent
USA
Public USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
Canada
Private /
independent
USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
USA
Subsidiary USA
Public USA
Biotech Financing Summary
All data supplied and available from Biotechgate
Eisai Co., Ltd. Pharma
Syntrix Biosystems, Inc. Therapeutics / Diagnostics
Kaketsuken Pharma
Eisai Co., Ltd. Pharma
Eisai Co., Ltd. Pharma
Oncothyreon Inc. Therapeutics / Diagnostics
KIYATEC Inc. R&D Services
BioCryst
Pharmaceuticals, Inc.
Therapeutics / Diagnostics
ProQR Therapeutics BV Therapeutics / Diagnostics
Foamix Pharmaceuticals
Ltd.
Pharma
Tokai Pharmaceuticals,
Inc.
Therapeutics / Diagnostics
Cardiorentis AG Therapeutics / Diagnostics
MGB Biopharma Limited Therapeutics / Diagnostics
Qu Biologics Inc. Therapeutics / Diagnostics
Avraham
Pharmaceuticals
Therapeutics / Diagnostics
Parion Sciences, Inc. Therapeutics / Diagnostics
Avinger Medical Technology
Biotech Financing Summary
All data supplied and available from Biotechgate – www.biotechgate.com
3.0 Other Research
grants
Therapeutics / Diagnostics 1.7 Other Research
grants
3.0 Other Research
grants
3.8 Other Research
grants
2.0 Other Research
grants
Therapeutics / Diagnostics 20.0 Other Post-IPO
2.0 Other Research
grants
Therapeutics / Diagnostics 2.0 Other Research
grants
Therapeutics / Diagnostics 98.0 Other IPO
40.0 Other IPO
Diagnostics 97.2 Other IPO
Therapeutics / Diagnostics 58.1 UD Equity -
Later stage
Therapeutics / Diagnostics 6.5 UD Equity -
Start-up
Therapeutics / Diagnostics 4.6 UD Equity -
Second
stage
Therapeutics / Diagnostics 4.5 UD Equity -
Later stage
/ Diagnostics 3.0 Other Research
grants
Medical Technology 35.0 UD Equity -
Later stage
www.biotechgate.com
9
Public Japan
Private /
independent
USA
Private /
independent
Japan
Public Japan
Public Japan
Public USA
Private /
independent
USA
Public USA
Public Netherlands
Public Israel
Public USA
Private /
independent
Switzerland
Private /
independent
United
Kingdom
Private /
independent
Canada
Private /
independent
Israel
Private /
independent
USA
Private /
independent
USA
Biotech Financing Summary
All data supplied and available from Biotechgate
NewLeaf Symbiotics Biotechnology - other
Molecular Templates Therapeutics / Diagnostics
nLife Therapeutics SL Therapeutics / Diagnostics
Genisphere, LLC R&D Services
Scholar Rock Therapeutics / Diagnostics
Affimed Therapeutics AG Therapeutics / Diagnostics
Corindus Vascular
Robotics
Medical Technology
ReWalk Robotics Ltd. Medical Technology
AM-Pharma Therapeutics / Diagnostics
ViaCyte, Inc. Therapeutics / Diagnostics
Cellerant Therapeutics,
Inc.
Therapeutics / Diagnostics
Lq3 Pharmaceutical Therapeutics / Diagnostics
Airway Therapeutics,
LLC
Therapeutics / Diagnostics
Harpoon Medical, Inc. Medical Technology
Alizé Pharma Therapeutics / Diagnostics
Tryton Medical, Inc. Medical Technology
Euclises
Pharmaceuticals, Inc.
Therapeutics / Diagnostics
Biotech Financing Summary
All data supplied and available from Biotechgate – www.biotechgate.com
other 17.0 Series B / 2.
Round
Equity -
Second
stage
Therapeutics / Diagnostics 3.5 Series C / 3.
Round
Equity -
Start-up
Therapeutics / Diagnostics 9.7 UD Equity -
First stage
2.0 Other Other
Therapeutics / Diagnostics 20.0 Series A / 1.
Round
Equity -
Start-up
Therapeutics / Diagnostics 56.0 Other IPO
Medical Technology 26.6 Other Post-IPO
Medical Technology 36.0 Other IPO
Therapeutics / Diagnostics 15.7 UD Equity -
Second
stage
Therapeutics / Diagnostics 16.6 Other Research
grants
Therapeutics / Diagnostics 47.5 Other Government
subvention
Therapeutics / Diagnostics 10.0 Series A / 1.
Round
Equity -
Seed
Therapeutics / Diagnostics 4.6 Series A / 1.
Round
Equity -
Start-up
Medical Technology 3.2 Series A / 1.
Round
Equity -
Seed
Therapeutics / Diagnostics 6.5 Series A / 1.
Round
Equity -
First stage
Medical Technology 20.0 UD Equity -
Later stage
Therapeutics / Diagnostics 1.3 Series A / 1.
Round
Equity -
Start-up
www.biotechgate.com
10
Private /
independent
USA
Private /
independent
USA
Private /
independent
Spain
Private /
independent
USA
Private /
independent
USA
Public Germany
Public USA
Public Israel
Private /
independent
Netherlands
Private /
independent
USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
France
Private /
independent
USA
Private /
independent
USA
Biotech Financing Summary
All data supplied and available from Biotechgate
Poxel SA Therapeutics / Diagnostics
SGB, Inc Biotechnology - other
Avelas Biosciences, Inc. Medical Technology
NanoViricides, Inc. Therapeutics / Diagnostics
Edge Therapeutics, Inc. Therapeutics / Diagnostics
Sonendo, Inc. Medical Technology
Flex Pharma Inc. Therapeutics / Diagnostics
Diffusion
Pharmaceuticals, LLC
Therapeutics / Diagnostics
Stealth Therapeutics,
Inc
Medical Technology
Biocartis SA R&D Services
Fractyl Laboratories,
Inc.
Medical Technology
Clovis Oncology Therapeutics / Diagnostics
Depomed, Inc. Pharma
Immunophotonics Inc Therapeutics / Diagnostics
AcuFocus, Inc. Medical Technology
WHILL, Inc. Medical Technology
Clearside Biomedical,
Inc.
Therapeutics / Diagnostics
Biotech Financing Summary
All data supplied and available from Biotechgate – www.biotechgate.com
Therapeutics / Diagnostics 12.9 Series B / 2.
Round
Equity -
Second
stage
other 11.0 Series C / 3.
Round
Equity -
First stage
Medical Technology 7.4 Series B / 2.
Round
Equity -
Start-up
Therapeutics / Diagnostics 7.5 Other Post-IPO
Therapeutics / Diagnostics 10.0 Other Debt
financing
Medical Technology 35.0 UD Equity -
Start-up
Therapeutics / Diagnostics 40.0 Other n/a
Therapeutics / Diagnostics 3.5 UD Equity -
Second
stage
Medical Technology 0.4 UD Equity -
Seed
83.3 UD Equity -
Second
stage
Medical Technology 40.0 Series C / 3.
Round
Equity -
Later stage
Therapeutics / Diagnostics 250.0 Other Convertible
loan
300.0 Other Convertible
loan
Therapeutics / Diagnostics 1.8 Series A / 1.
Round
Equity -
Start-up
Medical Technology 21.0 UD Equity -
Start-up
Medical Technology 11.0 Series A / 1.
Round
Equity -
Start-up
Therapeutics / Diagnostics 16.0 Series B / 2.
Round
Equity -
First stage
www.biotechgate.com
11
Private /
independent
France
Private /
independent
USA
Private /
independent
USA
Public USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
Switzerland
Private /
independent
USA
Public USA
Public USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
USA
Private /
independent
USA
Biotech Financing Summary
All data supplied and available from Biotechgate
Mapp
Biopharmaceutical, Inc.
Therapeutics / Diagnostics
Affimed Therapeutics AG Therapeutics / Diagnostics
Zai Laboratory, Inc. R&D Services
Affimed Therapeutics AG Therapeutics / Diagnostics
UD: Undisclosed
Biotech Financing Summary
All data supplied and available from Biotechgate – www.biotechgate.com
Therapeutics / Diagnostics 24.9 Other Research
grants
Therapeutics / Diagnostics 13.6 Other Debt
financing
30.0 Series A / 1.
Round
n/a
Therapeutics / Diagnostics 15.1 Series E / 5.
Round
Equity -
Later stage
www.biotechgate.com
12
Private /
independent
USA
Public Germany
Private /
independent
China
Public Germany
Biotech Financing Summary
All data supplied and available from Biotechgate
About this summary
The Biotech Financing Summary is published on a monthly basis by Venture Valuation and
can be downloaded for free either from our newsletter or from the website
http://www.biotechgate.com/services/v3/statisticsvcdeal
The data used for this summary is taken from Venture Valuation’s global Biotech and life
science database Biotechgate. Biotechgate is a popular source for life sciences company
and licensing deals information. If you are in
hesitate to contact us and to apply for a trial.
Click here to learn more about
Venture Valuation
Kasernenstrasse 11
8004 Zurich
Switzerland
Phone: +41 (43) 321 86 60
Web: www.venturevaluation.com
Email: [email protected]
Copyright © 2014 Venture Valuation VV Ltd. All rights reserved. This report is provided
for information purposes only. All information regarding financing rounds, deal
summaries and merger and acquisition transactions was obtained from company
websites, press-releases, conference profiles and different
above information can also be accessed on the Biotechgate website. All graphical
information was provided via Biotechgate. While the information contained herein has
been obtained from sources deeme
guarantees that it is accurate, complete, timely, or sequential. For more information
about Biotech companies, including deal, licensing and financing round details, please
visit the Biotechgate website at
Biotech Financing Summary
All data supplied and available from Biotechgate – www.biotechgate.com
The Biotech Financing Summary is published on a monthly basis by Venture Valuation and
can be downloaded for free either from our newsletter or from the website
om/services/v3/statisticsvcdeal
The data used for this summary is taken from Venture Valuation’s global Biotech and life
science database Biotechgate. Biotechgate is a popular source for life sciences company
and licensing deals information. If you are interested in learning more, please do not
hesitate to contact us and to apply for a trial.
about Biotechgate »
www.venturevaluation.com
Email: [email protected]
Venture Valuation VV Ltd. All rights reserved. This report is provided
for information purposes only. All information regarding financing rounds, deal
summaries and merger and acquisition transactions was obtained from company
nference profiles and different industry newsletters. The
above information can also be accessed on the Biotechgate website. All graphical
information was provided via Biotechgate. While the information contained herein has
been obtained from sources deemed reliable, Venture Valuation VV Ltd makes no
guarantees that it is accurate, complete, timely, or sequential. For more information
about Biotech companies, including deal, licensing and financing round details, please
visit the Biotechgate website at www.biotechgate.com
www.biotechgate.com
13
The Biotech Financing Summary is published on a monthly basis by Venture Valuation and
can be downloaded for free either from our newsletter or from the website
The data used for this summary is taken from Venture Valuation’s global Biotech and life
science database Biotechgate. Biotechgate is a popular source for life sciences company
terested in learning more, please do not
Venture Valuation VV Ltd. All rights reserved. This report is provided
for information purposes only. All information regarding financing rounds, deal
summaries and merger and acquisition transactions was obtained from company
industry newsletters. The
above information can also be accessed on the Biotechgate website. All graphical
information was provided via Biotechgate. While the information contained herein has
d reliable, Venture Valuation VV Ltd makes no
guarantees that it is accurate, complete, timely, or sequential. For more information
about Biotech companies, including deal, licensing and financing round details, please
![ARGOS THERAPEUTICS INC - Annual report...2xu'hyhorsphqw3urjudpv 7khiroorzlqjwdeohvxppdul]hvrxughyhorsphqwsurjudpviru$*6 dqg$*6 3urgxfw&dqglgdwh 3ulpdu\,qglfdwlrq 6wdwxv $*6 p5&&](https://static.fdocuments.in/doc/165x107/60fca001e9e18300f340f51d/argos-therapeutics-inc-annual-report-2xuhyhorsphqw3urjudpv-7khiroorzlqjwdeohvxppdulhvrxughyhorsphqwsurjudpviru6.jpg)
